Target 5000: a standardized all-Ireland pathway for the diagnosis and management of inherited retinal degenerations

• Published in: Orphanet journal of rare diseases 2021-05, Vol.16 (1), p.200-200, Article 200
• Main Authors: Stephenson, Kirk A J, Zhu, Julia, Wynne, Niamh, Dockery, Adrian, Cairns, Rebecca M, Duignan, Emma, Whelan, Laura, Malone, Conor P, Dempsey, Hilary, Collins, Karen, Routledge, Shana, Pandey, Rajiv, Crossan, Elaine, Turner, Jacqueline, O'Byrne, James J, Brady, Laura, Silvestri, Giuliana, Kenna, Paul F, Farrar, G Jane, Keegan, David J
• Format: Article
• Language: English
• Subjects: Care and treatment; Clinical diagnostic algorithm; Clinical trials; Diabetic retinopathy; Diagnosis; Eye diseases; Genes; Genetic counseling; Genetic diagnosis; Genetic disorders; Genetic screening; Genetics; Genomes; Genotype & phenotype; Genotypes; Genotyping; Health services; Inherited retinal degenerations; Laboratories; Letter to the Editor; Macular degeneration; Medical personnel; Medical research; Methods; Molecular diagnostic techniques; Ocular genetics; Ontology; Pathogenicity; Patients; Phenotypes; Phenotyping; Population; Public and patient involvement; Retina; Retinal degeneration; Retinal dystrophy; Whole genome sequencing
• ISSN: 1750-1172; 1750-1172
• DOI: 10.1186/s13023-021-01841-1

Inherited retinal degenerations (IRD) are rare genetic disorders with > 300 known genetic loci, manifesting variably progressive visual dysfunction. IRDs were historically underserved due to lack of effective interventions. Many novel therapies will require accurate diagnosis (phenotype and genotype), thus an efficient and effective pathway for assessment and management is required. Using surveys of existing practice patterns and advice from international experts, an all-Ireland IRD service (Target 5000) was designed. Detailed phenotyping was followed by next generation genetic sequencing in both a research and accredited laboratory. Unresolved pedigrees underwent further studies (whole gene/whole exome/whole genome sequencing). Novel variants were interrogated for pathogenicity (cascade screening, in silico analysis, functional studies). A multidisciplinary team (MDT; ophthalmologists, physicians, geneticists, genetic counsellors) reconciled phenotype with genotype. A bespoke care plan was created for each patient comprising supports, existing interventions, and novel therapies/clinical trials. Prior to Target 5000, a significant cohort of patients were not engaged with healthcare/support services due to lack of effective interventions. Pathogenic or likely pathogenic variants in IRD-associated genes were detected in 62.3%, with 11.6% having variants of unknown significance. The genotyping arm of Target 5000 allowed a 42.73% cost saving over independent testing, plus the value of MDT expertise/processing. Partial funding has transferred from charitable sources to government resources. Target 5000 demonstrates efficacious and efficient clinical/genetic diagnosis, while discovering novel IRD-implicated genes/variants and investigating mechanisms of disease and avenues of intervention. This model could be used to develop similar IRD programmes in small/medium-sized nations.